Abstract
Alemtuzumab is a humanized CD52-specific monoclonal antibody that is increasingly used off-label as an induction agent in solid organ transplantation, particularly in the setting of maintenance immunosuppression minimization protocols. In this review, we briefly discuss this agent's mechanisms of action and summarize evidence supporting its use in this clinical setting.
| Original language | English |
|---|---|
| Pages (from-to) | 1545-1547 |
| Number of pages | 3 |
| Journal | Transplantation |
| Volume | 84 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2007 |
| Externally published | Yes |
Keywords
- Alemtuzumab
- Immunosuppression
- Lymphocyte depletion
- Monoclonal antibody